Season 2 (2021-2030)

Metabolic - Discovery (31)

Modality Indication Targets Stage Company Project No. Detail
1 Development of a ZBP1-Targeting Small Molecule Therapeutic for Alcoholic Liver Disease: Lead Compound Identification Through Inhibition of Inflammatory Cell Death Pathways
Small molecules Hepatic disease ZBP1 Hit UNIST RS-2025-02222987
2 Drug Development for NASH and obesity
rProtein NASH CXCR7 Hit Yonsei University HN22C0645
3 Treatment of NASH using autophagy enhancer ameliorateing organelle stress
Small molecules NASH TFEB Hit LysoTech HN22C0278
4 Developing treatment for metabolic disease targeting PPARγ phosphorylation based on adipocyte remodeling
Small molecules Diabetes, Obesity PPARγ S273 Hit Korea Research Institute of Bioscience and Biotechnology HN22C0120
5 Discovery of hit and lead compounds based on oral IP6 kinase inhibition to treat obesity
Small molecules Obesity IP6K Hit Korea Advanced Institute of Science and Technology HN21C1265
6 Development of PAK4 inhibitor as anti-diabetes drug
Small molecules Diabetes PAK4 Hit Jeonbuk National University HN21C0447
7 Development of lead compounds as a sphingomyelin synthase 1 inhibitor to reduce the hepatocyte lipotoxicity for the treatment of liver cirrhosis
Small molecules Cirrhosis SMS1 Hit Seoul National University HN21C1150
8 Development of HIT compounds of MLKL inhibitors for treatment of nonalcoholic fatty liver disease
Small molecules NASH MLKL Hit Hanyang University HN21C1149
9 Development of lead for intestinal glucotonic therapeutics based on atypical PKC activation for treatment of metabolic syndrome
Small molecules Diabetes, Obesity Atypical PKC Hit Yonsei University HN21C1008
10 PG-110: A Bi-Specific ActRII/Myostatin Blocker for Metabolic and Musculoskeletal Health
Antibody Obesity ActRII/Myostatin Lead ProGen Co., Ltd. RS-2025-02213767
11 Lead compound generation of DYRK1B inhibitor for NASH treatment
Small molecules Liver fibrosis DYRK1B Lead Therasid Bioscience Inc. RS-2023-00283399
12 Discovery of lead compounds based on increase of lipolysis and energy expenditure to treat obesity
Small molecules Obesity ALK7 Lead Gachon University RS-2023-00282576
13 Development of STK25 inhibitor for treatment of nonalcoholic steatohepatitis
Small molecules NASH STK25 Lead Korea Research Institute of Chemical Technology RS-2023-00218351
14 Drug development for Duchenne muscular dystrophy by increasing mRNA stability
Small molecules Duchenne muscular dystrophy NMD Lead RiboTech HN22C0723
15 Discovery of dual A2A adeosine receptor agonist/A3 adenosine antagonist as anti-obesity drug
Small molecules Obesity A2AAR, A3AR Lead Seoul National University HN22C0687
16 Development of peripheral cannabinoid 1 receptor antagonists targeting diabetes and metabolic disease using AI/CADD-based technology
Small molecules Diabetes CB1R Lead Sungkyunkwan University HN22C0203
17 Development of a PPAR/AMPK dual agonist for treatment of diabetes and metabolic syndrome
Small molecules Diabetes PPARγ, AMPA Lead Seoul National University Hospital HN21C0497
18 Development of Lead compounds as a Deubiquitinase USP1 Inhibitor for Non-Alcoholic Fat Liver Diseases Therapy
Small molecules NASH USP1 Lead Yonsei University HN21C0153
19 Fat-targeting non-viral gene therapeutics for the treatment of obesity and obesity-induced metabolic syndrome
Gene & Nucleic acids Obesity FABP4, FABP5 Lead Hanyang University HN21C0885
20 A Study on the Hit to Lead Optimization of Resistin Targeting Antibodies as a Treatment for Non-Alcoholic Fatty Liver Disease
Antibody NASH Resistin, CAP1 Lead Seoul National University Hospital HN21C0524
21 Development of a novel small-molecule anti-obesity drug based on inhibition of ****
Small molecules Obesity **** Candidate JW Pharmaceutical RS-2025-25455548
22 Developing a bispecific siRNA therapy for dyslipidemia patients with complex symptoms(Csi103)
Gene & Nucleic acids Dyslipidemia PCSK9, APOC3 Candidate Curigin Co., Ltd. RS-2025-02213434
23 Development of candidate compounds as PPARgamma/AMPK dual agonists for treatment of diabetes
Small molecules Diabetes PPARr, AMPK Candidate dalimbiotech RS-2025-02172988
24 Development of Therapeutics for Liver Fibrosis through the Discovery of Collagen Inhibitors
Small molecules Liver fibrosis Serpin Family Candidate Daewoong Pharmaceutical RS-2024-00463096
25 Adipocyte-Targeted Gene Therapy via Dual FABP4/FABP5 Fat Accumulation Factor Silencing
Gene & Nucleic acids Obesity, type 2 diabetes FABP4/5 Candidate Cursus Bio Inc. RS-2024-00459648
26 Development of Treatment Drugs for Obesity using Concomitant Administration of Microbiome Consortia
Other-Bio. Obesity Bacteroides vulgatus, Roseburia intestinalis, Akkermansia muciniphila Candidate KoBiolabs Inc. RS-2023-00219249
27 Development of KARS1-target drug candidate with broad and high efficacy for treatment of NASH (non-alcoholic steatohepatitis)
Small molecules NASH KARS1 Candidate Zymedi RS-2023-00218823
28 Establishing of Fc-flagellin-based candidate drug (MSP-306) for NASH treatment and entering non-clinical trials
rProtein NASH TLR5 Candidate MediSpan HN22C0599
29 A study on derivation and optimization of non-clinical candidates for nonalcoholic steatohepatitis gene therapy
Gene & Nucleic acids NASH CR-P1 Candidate Curogen Technology HN21C0805
30 Development of a preclinical candidate of a UniStac-based long-acting tetra-specific drug for NASH
rProtein NASH FGF21, GLP-1, GCG, a-cytokine Candidate Onegene Biotechnology Inc. HN21C0561
31 Development of long-acting human growth hormone receptor antagonist by next generation technology
rProtein Acromegaly hGH receptor Candidate Alteogen Inc. HN21C0535
BACK